» Articles » PMID: 27141277

Reversible Pulmonary Artery Hypertension in Association with Interferon-beta Therapy for Multiple Sclerosis

Overview
Journal Iran J Neurol
Date 2016 May 4
PMID 27141277
Citations 2
Authors
Affiliations
Soon will be listed here.
Citing Articles

Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.

Atabati E, Dehghani-Samani A, Mortazavimoghaddam S Can J Respir Ther. 2020; 56:1-9.

PMID: 33274259 PMC: 7690312. DOI: 10.29390/cjrt-2020-021.


Pulmonary arterial hypertension associated with interferon therapy: a population-based study.

Papani R, Duarte A, Lin Y, Kuo Y, Sharma G Multidiscip Respir Med. 2017; 12:1.

PMID: 28105332 PMC: 5240202. DOI: 10.1186/s40248-016-0082-z.

References
1.
George P, Badiger R, Alazawi W, Foster G, Mitchell J . Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135(1):44-53. DOI: 10.1016/j.pharmthera.2012.03.006. View

2.
Gibbons E, Promislow S, Davies R, Chandy G, Stewart D, Vladamir C . Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J. 2015; 22(5):263-5. PMC: 4596647. DOI: 10.1155/2015/181535. View

3.
Govern E, Judge E, Kavanagh E, Gaine S, Lynch T . Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?. Mult Scler Relat Disord. 2015; 4(3):284-6. DOI: 10.1016/j.msard.2015.03.008. View

4.
Caravita S, Secchi M, Wu S, Pierini S, Paggi A . Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2012; 120(4):187-9. DOI: 10.1159/000335064. View

5.
Rot U, Horvat Ledinek A . Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. Clin Neurol Neurosurg. 2013; 115 Suppl 1:S79-81. DOI: 10.1016/j.clineuro.2013.09.027. View